{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:32:51Z","timestamp":1707525171110},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,7]]},"DOI":"10.7759\/cureus.43097","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T03:39:02Z","timestamp":1691465942000},"source":"Crossref","is-referenced-by-count":0,"title":["Malignant Perivascular Epithelioid Cell Neoplasm of Left Kidney Treated With Targeted Therapy: A Rare Case Report"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Haseeb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Sachdev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Sravani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandana","family":"Tadigotla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naga Anjani Bhaskar Srinivas","family":"Sunkara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Gadyalpatil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/541626","article-title":"\"Malignant\" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies","volume":"2012","author":"Bleeker JS","year":"2012","unstructured":"Bleeker JS, Quevedo JF, Folpe AL. \"Malignant\" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies. Sarcoma. 2012, 2012:541626. 10.1155\/2012\/541626","journal-title":"Sarcoma"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1043\/1543-2165-133.4.648","article-title":"Perivascular epithelioid cell tumor","volume":"133","author":"Armah HB","year":"2009","unstructured":"Armah HB, Parwani AV. Perivascular epithelioid cell tumor. Arch Pathol Lab Med. 2009, 133:648-54. 10.1043\/1543-2165-133.4.648","journal-title":"Arch Pathol Lab Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27800","article-title":"Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates","volume":"132","author":"Dickson MA","year":"2013","unstructured":"Dickson MA, Schwartz GK, Antonescu CR, Kwiatkowski DJ, Malinowska IA. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer. 2013, 132:1711-7. 10.1002\/ijc.27800","journal-title":"Int J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063564","article-title":"Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis","volume":"358","author":"Bissler JJ","year":"2008","unstructured":"Bissler JJ, McCormack FX, Young LR, et al.. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008, 358:140-51. 10.1056\/NEJMoa063564","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318031ffff","article-title":"Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum","volume":"31","author":"Argani P","year":"2007","unstructured":"Argani P, Olgac S, Tickoo SK, et al.. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007, 31:1149-60. 10.1097\/PAS.0b013e318031ffff","journal-title":"Am J Surg Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181f17ac0","article-title":"A distinctive subset of PEComas harbors TFE3 gene fusions","volume":"34","author":"Argani P","year":"2010","unstructured":"Argani P, Aulmann S, Illei PB, et al.. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010, 34:1395-406. 10.1097\/PAS.0b013e3181f17ac0","journal-title":"Am J Surg Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199203000-00013","article-title":"PEC and sugar","volume":"16","author":"Bonetti F","year":"1992","unstructured":"Bonetti F, Pea M, Martignoni G, Zamboni G. PEC and sugar. Am J Surg Pathol. 1992, 16:307-8. 10.1097\/00000478-199203000-00013","journal-title":"Am J Surg Pathol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq044","article-title":"Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa","volume":"21","author":"Italiano A","year":"2010","unstructured":"Italiano A, Delcambre C, Hostein I, et al.. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010, 21:1135-7. 10.1093\/annonc\/mdq044","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13061","article-title":"Malignant PEComa","volume":"45","author":"Haiges D","year":"2018","unstructured":"Haiges D, Kurz P, Laaff H, Meiss F, Kutzner H, Technau-Hafsi K. Malignant PEComa. J Cutan Pathol. 2018, 45:84-9. 10.1111\/cup.13061","journal-title":"J Cutan Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.12263","article-title":"Malignant epithelioid soft tissue tumours- a pathologist's perspective with review of literature","volume":"12","author":"Dey B","year":"2020","unstructured":"Dey B, Srinivas BH, Badhe B, Nachiappa Ganesh R, Gochhait D, Toi PC, Jinkala S. Malignant epithelioid soft tissue tumours- a pathologist's perspective with review of literature. Cureus. 2020, 12:e12263. 10.7759\/cureus.12263","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2015.06.003","article-title":"PEComa: morphology and genetics of a complex tumor family","volume":"19","author":"Thway K","year":"2015","unstructured":"Thway K, Fisher C. PEComa: morphology and genetics of a complex tumor family. Ann Diagn Pathol. 2015, 19:359-68. 10.1016\/j.anndiagpath.2015.06.003","journal-title":"Ann Diagn Pathol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.2981","article-title":"Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors","volume":"28","author":"Wagner AJ","year":"2010","unstructured":"Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al.. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010, 28:835-40. 10.1200\/JCO.2009.25.2981","journal-title":"J Clin Oncol"},{"key":"ref13","article-title":"A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience","volume":"34","author":"Benson C","year":"2014","unstructured":"Benson C, Vitfell-Rasmussen J, Maruzzo M, et al.. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res. 2014, 34:3663-8.","journal-title":"Anticancer Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0288","article-title":"Role of chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in advanced perivascular epithelioid cell tumors (PEComas)","volume":"25","author":"Sanfilippo R","year":"2019","unstructured":"Sanfilippo R, Jones RL, Blay JY, et al.. Role of chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in advanced perivascular epithelioid cell tumors (PEComas). Clin Cancer Res. 2019, 25:5295-300. 10.1158\/1078-0432.CCR-19-0288","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-10-181","article-title":"Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor","volume":"10","author":"Gennatas C","year":"2012","unstructured":"Gennatas C, Michalaki V, Kairi PV, Kondi-Paphiti A, Voros D. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol. 2012, 10:181. 10.1186\/1477-7819-10-181","journal-title":"World J Surg Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10163705","article-title":"Efficacy of sirolimus treatment in PEComa-10 years of practice perspective","volume":"10","author":"\u015awitaj T","year":"2021","unstructured":"\u015awitaj T, Sobiborowicz A, Teterycz P, et al.. Efficacy of sirolimus treatment in PEComa-10 years of practice perspective. J Clin Med. 2021, 10:3705. 10.3390\/jcm10163705","journal-title":"J Clin Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.20305","article-title":"Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate","volume":"45","author":"Rigby H","year":"2005","unstructured":"Rigby H, Yu W, Schmidt MH, Fernandez CV. Lack of response of a metastatic renal perivascular epithelial cell tumor (PEComa) to successive courses of DTIC based-therapy and imatinib mesylate. Pediatr Blood Cancer. 2005, 45:202-6. 10.1002\/pbc.20305","journal-title":"Pediatr Blood Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/169934-malignant-perivascular-epithelioid-cell-neoplasm-of-left-kidney-treated-with-targeted-therapy-a-rare-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:10Z","timestamp":1707508930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/169934-malignant-perivascular-epithelioid-cell-neoplasm-of-left-kidney-treated-with-targeted-therapy-a-rare-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.43097","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,7]]}}}